Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study

ConclusionsBMD was increased significantly during romosozumab treatment at the lumbar spine, and the femoral neck, respectively, at 1  year in HD patients. Hypocalcemia occurred but without any intolerable event. There was no apparent increase in CVD events during 1 year of study, suggesting romosozumab as a promising agent for HD patients with severe osteoporosis.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research